Biopolymer-coated gold nanoparticles inhibit human insulin amyloid fibrillation.
Amyloid
/ chemistry
Amyloidosis
/ prevention & control
Biopolymers
/ chemistry
Chitosan
/ chemistry
Circular Dichroism
/ methods
Coated Materials, Biocompatible
/ chemistry
Dextrins
/ chemistry
Dynamic Light Scattering
Gold
/ chemistry
Humans
Insulin
/ chemistry
Metal Nanoparticles
/ administration & dosage
Microscopy, Atomic Force
/ methods
Microscopy, Electron, Transmission
/ methods
Spectrophotometry
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 05 2020
12 05 2020
Historique:
received:
15
02
2020
accepted:
06
04
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Deposits of protein misfolding and/or aggregates are a pathological hallmark of amyloid-related diseases. For instance, insulin amyloid fibril deposits have been observed in patients with insulin-dependent diabetes mellitus after insulin administration. Here, we report on the use of AuNPs functionalized with linear- (i.e. dextrin and chitosan) and branched- (i.e. dextran-40 and dextran-10) biopolymers as potential agents to inhibit insulin fibril formation. Our dynamic light scattering analyses showed a size decrease of the amyloid fibrils in the presence of functionalized AuNPs. Circular dichroism spectroscopy as well as enzyme-linked immunosorbent assay data demonstrated that the secondary structural transition from α-helix to β-sheet (which is characteristic for insulin amyloid fibril formation) was significantly suppressed by all biopolymer-coated AuNPs, and in particular, by those functionalized with linear biopolymers. Both transmission electron microscopy and atomic force microscopy analyses showed that the long thick amyloid fibrils formed by insulin alone become shorter, thinner or cluster when incubated with biopolymer-coated AuNPs. Dextrin- and chitosan-coated AuNPs were found to be the best inhibitors of the fibril formation. Based on these results, we propose a mechanism for the inhibition of insulin amyloid fibrils: biopolymer-coated AuNPsstrongly interact with the insulin monomers and inhibit the oligomer formation as well as elongation of the protofibrils.Moreover, cytotoxicity experiments showed that AuNP-insulin amyloid fibrils are less toxic compared to insulin amyloid fibrils alone. Our results suggest that both dextrin- and chitosan-AuNPs could be used as therapeutic agents for the treatment of amyloid-related disorders.
Identifiants
pubmed: 32398693
doi: 10.1038/s41598-020-64010-7
pii: 10.1038/s41598-020-64010-7
pmc: PMC7217893
doi:
Substances chimiques
Amyloid
0
Biopolymers
0
Coated Materials, Biocompatible
0
Dextrins
0
Insulin
0
Gold
7440-57-5
Chitosan
9012-76-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7862Références
Dobson, C. M. Protein folding and misfolding. Nature 426, 884–890 (2003).
doi: 10.1038/nature02261
Lansbury, P. T. Jr & Rochet, J. C. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60–68 (2000).
doi: 10.1016/S0959-440X(99)00049-4
Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–366 (2006).
doi: 10.1146/annurev.biochem.75.101304.123901
Dobson, C. M. The Structural Basis of Protein Folding and its Links with Human Disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 133–145 (2001).
doi: 10.1098/rstb.2000.0758
Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–1203 (2012).
doi: 10.1016/j.cell.2012.02.022
Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10, S10–S17 (2004).
doi: 10.1038/nm1066
Dobson, C. M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15, 3–16 (2004).
doi: 10.1016/j.semcdb.2003.12.008
Akkermans, C. et al. Shear pulses nucleate fibril aggregation. Food Biophys. 1, 144–150 (2006).
doi: 10.1007/s11483-006-9012-5
Giri, K., Bhattacharyya, N. P. & Basak, S. pH-dependent self-assembly of polyalanine peptides. Biophys. J. 92, 293–302 (2007).
doi: 10.1529/biophysj.106.091769
Lee, G. et al. Self-assembled amyloid fibrils with controllable conformational heterogeneity. Sci Rep 5, 16220 (2015).
doi: 10.1038/srep16220
Bowsher, R. R. et al. Sensitive RIA for the Specific determination of insulin lispro. Clin. Chem. 45, 104–110 (1999).
doi: 10.1093/clinchem/45.1.104
Brange, J., Andersen, L., Laursen, E. D., Meyn, G. & Rasmussen, E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86, 517–525 (1997).
doi: 10.1021/js960297s
Shikama, Y. et al. Localized Amyloidosis at the Site of Repeated Insulin Injection in a Diabetic Patient. Inter Med. 49, 397–401 (2010).
doi: 10.2169/internalmedicine.49.2633
Yashdeep, G., Gaurav, S. & Rajiv, S. Insulin-derived amyloidosis. Indian J. Endocrinol Metab. 19, 174–177 (2015).
doi: 10.4103/2230-8210.146879
Zraika, S. et al. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53, 1046–1056 (2010).
doi: 10.1007/s00125-010-1671-6
Woods, R. J., Alarcon, J., McVey, E. & Pettis, R. J. Intrinsic fibrillation of fast-acting insulin analogs. J. Diabetes Sci. Technol. 6, 265–276 (2012).
doi: 10.1177/193229681200600209
Linse, S. et al. Nucleation of protein fibrillation by nanoparticles. Proc. Natl. Acad. Sci. USA 104, 8691–8696 (2007).
doi: 10.1073/pnas.0701250104
Rocha, S. et al. Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. Biophys. Chem. 137, 35–42 (2008).
doi: 10.1016/j.bpc.2008.06.010
Murphy, C. J. et al. Gold nanoparticles in biology: Beyond toxicity to cellular imaging. Acc Chem Res. 41, 1721–1730 (2008).
doi: 10.1021/ar800035u
Tiwari, P. M., Vig, K., Dennis, V. A. & Singh, S. R. Functionalized Gold Nanoparticles and Their Biomedical Applications. Nanomaterials 1, 31–63 (2011).
doi: 10.3390/nano1010031
Sardar, S., Pal, S., Maity, S., Chakraborty, J. & Halder, U. C. Amyloid fibril formation by beta-lactoglobulin is inhibited by gold nanoparticles. Int. J. Biol. Macromol. 69, 137–145 (2014).
doi: 10.1016/j.ijbiomac.2014.05.006
Moore, K. A. et al. Influence of gold nanoparticle surface chemistry and diameter upon Alzheimer’s disease amyloid-β protein aggregation. J. Biol. Eng. 11, 5 (2017).
doi: 10.1186/s13036-017-0047-6
Gao, G. et al. The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-β fibrillation. Nanoscale 9, 4107–4113 (2017).
doi: 10.1039/C7NR00699C
Elbassal, E. A. et al. Gold Nanoparticles as a Probe for Amyloid-β Oligomer and Amyloid Formation. J. Phys. Chem. C. 121, 20007–20015 (2017).
doi: 10.1021/acs.jpcc.7b05169
Wang, Y., Zhan, L. & Huang, C. Z. One-pot preparation of dextran-capped gold nanoparticles at room temperature and colorimetric detection of dihydralazine sulfate in uric samples. Anal. Methods. 2, 1982–1988 (2010).
doi: 10.1039/c0ay00470g
Bhumkar, D. R., Joshi, H. M., Sastry, M. & Pokharkar, V. B. Chitosan Reduced Gold Nanoparticles as Novel Carriers for Transmucosal Delivery of Insulin. Pharm Res. 24, 1415–1426 (2007).
doi: 10.1007/s11095-007-9257-9
Meesaragandla, B. et al. H-Bonding-mediated binding and charge reorganization of proteins on gold nanoparticles. Phys. Chem. Chem. Phys. 22, 4490–4500 (2020).
doi: 10.1039/C9CP06371D
Sotnikov, D. V., Berlina, A. N., Ivanov, V. S., Zherdev, A. V. & Dzantiev, B. B. Adsorption of proteins on gold nanoparticles: One or more layers? Colloids Surf. B: Biointerfaces 173, 557–563 (2019).
doi: 10.1016/j.colsurfb.2018.10.025
Underwood, S. & Mulvaney, P. Effect of the solution refractive-index on the color of gold colloids. Langmuir 10, 3427–3430 (1994).
doi: 10.1021/la00022a011
Xing, H. et al. Hierarchical Assembly of Nanostructured Coating for siRNA-Based Dual Therapy of Bone Regeneration and Revascularization. Biomaterials 235, 119784 (2020).
doi: 10.1016/j.biomaterials.2020.119784
Lu, N. H. et al. Examining the effects of dextran-based polymer-coated nanoparticles on amyloid fibrillogenesis of human insulin. Colloids Surf B Biointerfaces. 172, 674–683 (2018).
doi: 10.1016/j.colsurfb.2018.09.029
Nie, R. Z., Zhu, W., Peng, J. M., Ge, Z. Z. & Li, C. M. A-type dimeric epigallocatechin-3-gallate (EGCG) is a more potent inhibitor against the formation of insulin amyloid fibril than EGCG monomer. Biochimie. 125, 204–212 (2016).
doi: 10.1016/j.biochi.2016.03.011
Wang, S. S. S., Liu, K. N. & Han, T. C. Amyloid fibrillation and cytotoxicity of insulin are inhibited by the amphiphilic surfactants. Biochimica et Biophysica Acta 1802, 519–530 (2010).
doi: 10.1016/j.bbadis.2010.02.008
Buell, A. K. The growth of amyloid fibrils: rates and mechanisms. Biochemical Journal 476, 2677–2703 (2019).
doi: 10.1042/BCJ20160868
Kurouski, D., Gaudig, T. D., Deckert, V. & Lednev, I. K. Structure and composition of insulin fibril surfaces probed by TERS. J. Am. Chem. Soc. 134, 13323–13329 (2012).
doi: 10.1021/ja303263y